News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug ...

Separately, the company has reached 26 settlement agreements with generic manufacturers that have sought to market their own ...

In an interview to CNBC-TV18 pharma analyst, Anmol Ganjoo of Antique Stock Broking said Delhi High court's verdict on Januvia Generic will be a positive for Glenmark Pharma.

Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara and Fiasp/NovoLog. They accounted for $50.5 billion in total Part D covered prescription drug costs from June 2022 to May 2023, CMS said.